BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis

BIT:1BMY • US1101221083

51.02 EUR
-0.02 (-0.04%)
Last: Feb 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

1BMY gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of 1BMY get a neutral evaluation. Nothing too spectacular is happening here. 1BMY has a bad growth rate and is valued cheaply. 1BMY also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • 1BMY had positive earnings in the past year.
  • In the past year 1BMY had a positive cash flow from operations.
  • Of the past 5 years 1BMY 4 years were profitable.
  • 1BMY had a positive operating cash flow in 4 of the past 5 years.
1BMY.MI Yearly Net Income VS EBIT VS OCF VS FCF1BMY.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B

1.2 Ratios

  • The Return On Assets of 1BMY (6.23%) is comparable to the rest of the industry.
  • 1BMY's Return On Equity of 32.55% is fine compared to the rest of the industry. 1BMY outperforms 80.00% of its industry peers.
  • 1BMY has a Return On Invested Capital of 17.64%. This is in the better half of the industry: 1BMY outperforms 72.73% of its industry peers.
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROIC 17.64%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1BMY.MI Yearly ROA, ROE, ROIC1BMY.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • 1BMY has a Profit Margin (12.57%) which is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of 1BMY has grown nicely.
  • 1BMY's Operating Margin of 33.51% is amongst the best of the industry. 1BMY outperforms 81.82% of its industry peers.
  • In the last couple of years the Operating Margin of 1BMY has grown nicely.
  • The Gross Margin of 1BMY (73.15%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of 1BMY has remained more or less at the same level.
Industry RankSector Rank
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
1BMY.MI Yearly Profit, Operating, Gross Margins1BMY.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1BMY is creating value.
  • 1BMY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
1BMY.MI Yearly Shares Outstanding1BMY.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
1BMY.MI Yearly Total Debt VS Total Assets1BMY.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 2.33 indicates that 1BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of 1BMY (2.33) is comparable to the rest of the industry.
  • 1BMY has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as 1BMY would need 3.20 years to pay back of all of its debts.
  • 1BMY has a better Debt to FCF ratio (3.20) than 67.27% of its industry peers.
  • A Debt/Equity ratio of 2.41 is on the high side and indicates that 1BMY has dependencies on debt financing.
  • With a Debt to Equity ratio value of 2.41, 1BMY is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Altman-Z 2.33
ROIC/WACC2.06
WACC8.55%
1BMY.MI Yearly LT Debt VS Equity VS FCF1BMY.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.3 Liquidity

  • 1BMY has a Current Ratio of 1.27. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.27, 1BMY is doing worse than 60.00% of the companies in the same industry.
  • A Quick Ratio of 1.17 indicates that 1BMY should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.17, 1BMY is in the better half of the industry, outperforming 69.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.17
1BMY.MI Yearly Current Assets VS Current Liabilites1BMY.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 439.47% over the past year.
  • The Earnings Per Share has been decreasing by -0.92% on average over the past years.
  • Looking at the last year, 1BMY shows a decrease in Revenue. The Revenue has decreased by -0.22% in the last year.
  • 1BMY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.54% yearly.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%

3.2 Future

  • 1BMY is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.54% yearly.
  • 1BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.61% yearly.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1BMY.MI Yearly Revenue VS Estimates1BMY.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
1BMY.MI Yearly EPS VS Estimates1BMY.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.85, the valuation of 1BMY can be described as reasonable.
  • Based on the Price/Earnings ratio, 1BMY is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.68. 1BMY is valued rather cheaply when compared to this.
  • 1BMY is valuated reasonably with a Price/Forward Earnings ratio of 9.95.
  • Based on the Price/Forward Earnings ratio, 1BMY is valued cheaply inside the industry as 85.45% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, 1BMY is valued rather cheaply.
Industry RankSector Rank
PE 9.85
Fwd PE 9.95
1BMY.MI Price Earnings VS Forward Price Earnings1BMY.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 92.73% of the companies in the same industry are more expensive than 1BMY, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, 1BMY is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 8.05
EV/EBITDA 7.36
1BMY.MI Per share data1BMY.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • 1BMY has a very decent profitability rating, which may justify a higher PE ratio.
  • 1BMY's earnings are expected to decrease with -3.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 4.21%, 1BMY is a good candidate for dividend investing.
  • 1BMY's Dividend Yield is rather good when compared to the industry average which is at 1.89. 1BMY pays more dividend than 85.45% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.84, 1BMY pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.21%

5.2 History

  • The dividend of 1BMY is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 82.81% of the earnings are spent on dividend by 1BMY. This is not a sustainable payout ratio.
  • The Dividend Rate of 1BMY has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
1BMY.MI Yearly Income VS Free CF VS Dividend1BMY.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B
1BMY.MI Dividend Payout.1BMY.MI Dividend Payout, showing the Payout Ratio.1BMY.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BRISTOL-MYERS SQUIBB CO

BIT:1BMY (2/12/2026, 7:00:00 PM)

51.02

-0.02 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap103.86B
Revenue(TTM)48.19B
Net Income(TTM)6.04B
Analysts70.59
Price Target48.75 (-4.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.21%
Yearly Dividend2.04
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)7.65%
PT rev (3m)9.84%
EPS NQ rev (1m)-32.01%
EPS NQ rev (3m)-28.39%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)0.01%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)2.25%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)1.64%
Valuation
Industry RankSector Rank
PE 9.85
Fwd PE 9.95
P/S 2.56
P/FCF 8.05
P/OCF 7.41
P/B 6.64
P/tB N/A
EV/EBITDA 7.36
EPS(TTM)5.18
EY10.15%
EPS(NY)5.13
Fwd EY10.06%
FCF(TTM)6.34
FCFY12.42%
OCF(TTM)6.88
OCFY13.49%
SpS19.89
BVpS7.68
TBVpS-9.8
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.92
Profitability
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROCE 23.41%
ROIC 17.64%
ROICexc 23.19%
ROICexgc 118.19%
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
FCFM 31.86%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Debt/EBITDA 2.13
Cap/Depr 26.84%
Cap/Sales 2.75%
Interest Coverage 7.66
Cash Conversion 79.11%
Profit Quality 253.39%
Current Ratio 1.27
Quick Ratio 1.17
Altman-Z 2.33
F-Score6
WACC8.55%
ROIC/WACC2.06
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
EBIT growth 1Y44.7%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year13.96%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.73%
FCF growth 1Y10.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.78%
OCF growth 3YN/A
OCF growth 5YN/A

BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ

Can you provide the ChartMill fundamental rating for BRISTOL-MYERS SQUIBB CO?

ChartMill assigns a fundamental rating of 4 / 10 to 1BMY.MI.


Can you provide the valuation status for BRISTOL-MYERS SQUIBB CO?

ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (1BMY.MI). This can be considered as Undervalued.


Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?

BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a profitability rating of 5 / 10.


Can you provide the financial health for 1BMY stock?

The financial health rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 4 / 10.


Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?

The dividend rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 7 / 10 and the dividend payout ratio is 82.81%.